STAT+: Pharmalittle: Endo pays $50 million to settle opioid case; Senate mulls pegging drug prices to VA discounts
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to indulge our favorite hobby — promenading with the official mascot. We also plan to forage through the public library in search of a book or two and, if we have the willpower, we may also manicure the Pharmalot grounds, or maybe not. And what about you? This a fine time to enjoy the great outdoors. You could support your local economy by visiting a restaurant or two. Or you could reach out to someone special. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …
Senate lawmakers are actively considering pegging the prices Medicare pays for drugs to those drug makers offer to other government programs like the veterans health program, according to STAT. The proposal, known internally as domestic reference pricing, could have a multibillion-dollar impact on drug makers, which have long opposed allowing Medicare to negotiate over drug prices. Setting prices to what the Department of Veterans Affairs pay for medicines was one of seven options outlined in a June 7 slide deck by a Senate committee.
Continue to STAT+ to read the full story…
